Anti-PKA-RIB Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the CAP effector domain of PKA-RIB (PRKAR1B), validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
Q921L9
Size
100ug
Cat. #
RP1PKARIB

In stock

SKU
RP-PKARIB

Options

As low as: $130.00

Target Overview

PKA-RIB, encoded by the PRKAR1B gene, is the regulatory subunit type I-beta of the cAMP-dependent protein kinase A (PKA) holoenzyme. PKA is a tetrameric complex composed of two regulatory (R) subunits and two catalytic (C) subunits. In the absence of cAMP, the regulatory subunits bind to and inhibit the catalytic subunits. Upon cAMP binding to the regulatory subunits, the catalytic subunits are released and become enzymatically active. PRKAR1B is primarily localized to the cell membrane (UniProt Q921L9) and plays a critical role in compartmentalizing cAMP signaling within the cell. The type I regulatory subunits, including RIβ, differ from type II subunits in their subcellular localization patterns and tissue-specific expression. PRKAR1B is particularly abundant in brain, adipose tissue, and platelets, where it mediates tissue-specific responses to hormones and neurotransmitters that elevate intracellular cAMP levels. Researchers study PKA-RIB to understand spatiotemporal control of PKA signaling, A-kinase anchoring protein (AKAP) interactions, and the role of compartmentalized cAMP pathways in cellular physiology and disease.

Background

The cAMP-PKA signaling axis is one of the most extensively studied second messenger systems in eukaryotic cells. PKA-RIB (PRKAR1B) functions as a molecular switch that couples extracellular signals to intracellular phosphorylation cascades. Each regulatory subunit contains two tandem cAMP-binding domains and an N-terminal inhibitor sequence that occupies the active site of the catalytic subunit in the inactive holoenzyme. Binding of two cAMP molecules per regulatory subunit triggers a conformational change that leads to dissociation of the catalytic subunits, which then phosphorylate serine and threonine residues on downstream target proteins. The specificity of PKA signaling is in part determined by the subcellular localization of regulatory subunits through their interaction with A-kinase anchoring proteins (AKAPs). AKAPs tether PKA holoenzymes to distinct subcellular compartments, bringing the kinase into proximity with specific substrates and phosphatases. Recent work has identified AKAP9 variants associated with premature coronary artery disease, highlighting the clinical relevance of PKA anchoring and localization (Jiao et al., 2026). Dysregulation of PKA-RIB has been implicated in metabolic disorders, cardiac function, and neurological conditions. In adipocytes, PRKAR1B mediates lipolytic responses to catecholamines, and altered expression has been observed in obesity and insulin resistance models. Expression profiling studies have examined PRKAR1B transcript levels in agricultural animals as a marker of fat deposition and muscularity traits (Gomes et al., 2025). In neurons, PKA-RIB contributes to synaptic plasticity, long-term potentiation, and circadian rhythm regulation. Transcriptome analyses have revealed coordinate regulation of PRKAR1B with circadian and neurodevelopmental gene clusters in G protein-coupled receptor signaling pathways (Fukunaga et al., 2025). The regulatory subunit is also a node in broader signaling networks, with phosphoproteomic studies identifying cophosphoregulation patterns that link PKA activity to transcriptional regulators and chromatin modifiers (Lalu et al., 2025).

References

  1. Jiao Y et al (2026) A Novel A-Kinase-Anchoring Protein 9 Variant in Premature Coronary Artery Disease: A Case Series. Mol Genet Genomic Med. PubMed · 10.1002/mgg3.70159
  2. Gomes JD et al (2025) Pork Quality and Expression of Genes Involved in Muscularity and Fat Deposition in Different Commercial Lines and Sexes of Pigs. Animals (Basel). PubMed · 10.3390/ani15233363
  3. Fukunaga M et al (2025) Casomorphine-10 (CM-10) Peptide Orchestrates Circadian and Neurodevelopmental Gene Clusters via δ-Opioid Receptor Signaling: Insights from Transcriptome Analysis with δ-Opioid Receptor-Expressing HEK293 Cells. Life (Basel). PubMed · 10.3390/life15101636
  4. Lalu AC et al (2025) Mapping Cophosphoregulation Networks Linked to Transcriptional Regulator Bromodomain-Containing Protein 4. DNA Cell Biol. PubMed · 10.1089/dna.2025.0088

Additional Specifications

Gene Symbol PRKAR2A
UniProt ID Q921L9
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen Immunogen is proprietary and confidential. Immunogen generated in amino acid region 160-379.
Alternate Names PRKAR1B, Protein kinase A regulatory subunit type I-beta, cAMP-dependent protein kinase regulatory subunit type I-beta, PKA regulatory subunit RIβ, Tissue-specific extinguisher 1, TSE1

Frequently Asked Questions

What is the expected molecular weight of PKA-RIB on Western blot?

PKA-RIB (PRKAR1B) runs at approximately 46 kDa on Western blot under reducing conditions, corresponding to the full-length regulatory subunit I-beta. You may occasionally observe a doublet or minor higher molecular weight bands around 50-52 kDa, which can represent post-translational modifications such as phosphorylation. The protein is encoded by PRKAR1B and consists of 381 amino acids in humans. When probing brain or adipose tissue lysates, where PRKAR1B is highly expressed, you should see a clean band at 46 kDa. Always include a positive control lysate from these tissues to confirm antibody performance.

What dilution should I start with for PKA-RIB Western blot?

Start with a 1:1000 dilution in blocking buffer (5% non-fat milk or BSA in TBST) for Western blot applications. This is our validated dilution for this rabbit polyclonal antibody. Incubate overnight at 4°C for optimal signal. Depending on your tissue lysate and expression level, you may need to titrate between 1:500 and 1:2000. Brain and adipose lysates, which express high endogenous PRKAR1B levels, typically work well at 1:1000. For tissues with lower expression, start at 1:500 and optimize from there. Use 20-30 µg total protein per lane as a starting point.

Does this PKA-RIB antibody cross-react with other PKA regulatory subunits?

This antibody is raised against PKA-RIB (PRKAR1B) and is designed to specifically recognize the type I-beta regulatory subunit. There are four PKA regulatory subunits (RIα, RIβ, RIIα, RIIβ) with partial sequence homology, particularly within conserved cAMP-binding domains. Cross-reactivity with RIα (PRKAR1A) is possible given both are type I subunits, though they differ in molecular weight (RIα is approximately 43 kDa). We have validated specificity for human PRKAR1B. If you are working in a system expressing multiple R subunits, run parallel blots with isoform-specific controls or use siRNA knockdown to confirm band identity.

Will this antibody work in mouse or rat samples?

This antibody is validated for human PKA-RIB. Cross-reactivity with mouse and rat is predicted based on sequence homology between human and rodent PRKAR1B orthologs, which share greater than 90% identity at the protein level. Mouse PRKAR1B (UniProt Q921L9) is highly conserved in the immunogenic regions. However, cross-reactivity has not been formally validated by us. If working with mouse or rat tissue, we recommend testing the antibody at 1:500 to 1:1000 on brain or adipose lysates first, as these tissues show the highest PRKAR1B expression. Include a human lysate positive control on the same blot for comparison.

What are good positive and negative control tissues for PKA-RIB?

PKA-RIB is most abundant in brain tissue and adipose tissue, making these ideal positive controls. Neuronal cells and adipocytes rely heavily on compartmentalized cAMP signaling where PRKAR1B plays a key role in membrane-proximal PKA anchoring. For cell lines, SH-SY5Y (neuroblastoma) or primary neurons are good positive controls. As a negative control, consider tissues or cell lines with very low PRKAR1B expression, though true nulls are rare since PKA regulatory subunits are broadly expressed. A more practical negative control is lysate pretreated with siRNA against PRKAR1B or a PRKAR1B knockout cell line if available.

Can I use this PKA-RIB antibody for immunofluorescence or IHC?

Yes, Triple Point Biologics antibodies are validated for immunofluorescence and immunohistochemistry in addition to Western blot. For IF, start with a 1:100 to 1:200 dilution and optimize based on signal intensity and background. PKA-RIB localizes primarily to the plasma membrane, so expect peripheral or cortical staining patterns in cells with high expression. For IHC on paraffin-embedded tissue, antigen retrieval is typically required; citrate buffer (pH 6.0) heat-mediated retrieval is a standard starting point. Brain and adipose tissue sections serve as excellent positive controls. Titrate the antibody concentration to balance specific signal against background for your fixation and processing conditions.

How should I store this PKA-RIB antibody and what is the shelf life?

Store the antibody at -20°C in its original packaging. Avoid repeated freeze-thaw cycles, which can reduce antibody activity over time. For frequent use, consider making single-use aliquots (10-20 µL) upon receipt and storing them at -20°C or -80°C. Once thawed, an aliquot can be kept at 4°C for up to one month if supplemented with 0.02% sodium azide as a preservative. Do not add azide if you plan to use the antibody for applications involving HRP-conjugated detection, as azide inhibits peroxidase. Under proper storage at -20°C, the antibody remains stable for at least two years from the date of receipt.

Why am I seeing multiple bands with PKA-RIB antibody on Western blot?

Multiple bands can arise from several sources. PKA-RIB undergoes phosphorylation and other post-translational modifications that shift its mobility slightly, producing doublets or bands in the 46-52 kDa range. Proteolytic degradation during sample preparation can generate lower molecular weight fragments; ensure you use fresh protease inhibitors and keep samples on ice. Cross-reactivity with PKA-RIα (43 kDa) is also possible given sequence similarity between type I regulatory subunits. To troubleshoot, run a positive control (brain lysate) side-by-side, confirm your sample prep includes protease and phosphatase inhibitors, and consider treating lysate with lambda phosphatase to collapse phosphorylation-dependent bands into a single species.

Validation imagery coming soon

Western blot validation figures for RP-PKARIB will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

Also known as:

  • PRKAR1B
  • Protein kinase A regulatory subunit type I-beta
  • cAMP-dependent protein kinase regulatory subunit type I-beta
  • PKA regulatory subunit RIβ
  • Tissue-specific extinguisher 1
  • TSE1
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →